JP2008501705A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501705A5
JP2008501705A5 JP2007515611A JP2007515611A JP2008501705A5 JP 2008501705 A5 JP2008501705 A5 JP 2008501705A5 JP 2007515611 A JP2007515611 A JP 2007515611A JP 2007515611 A JP2007515611 A JP 2007515611A JP 2008501705 A5 JP2008501705 A5 JP 2008501705A5
Authority
JP
Japan
Prior art keywords
compound
formula
composition
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007515611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501705A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019549 external-priority patent/WO2005121065A2/en
Publication of JP2008501705A publication Critical patent/JP2008501705A/ja
Publication of JP2008501705A5 publication Critical patent/JP2008501705A5/ja
Withdrawn legal-status Critical Current

Links

JP2007515611A 2004-06-03 2005-06-02 ジアミンβ2アドレナリン作用性レセプターアゴニスト Withdrawn JP2008501705A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57656004P 2004-06-03 2004-06-03
PCT/US2005/019549 WO2005121065A2 (en) 2004-06-03 2005-06-02 DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS

Publications (2)

Publication Number Publication Date
JP2008501705A JP2008501705A (ja) 2008-01-24
JP2008501705A5 true JP2008501705A5 (cg-RX-API-DMAC7.html) 2008-07-17

Family

ID=35115813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515611A Withdrawn JP2008501705A (ja) 2004-06-03 2005-06-02 ジアミンβ2アドレナリン作用性レセプターアゴニスト

Country Status (14)

Country Link
US (2) US7402673B2 (cg-RX-API-DMAC7.html)
EP (1) EP1751086A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008501705A (cg-RX-API-DMAC7.html)
CN (1) CN1984876A (cg-RX-API-DMAC7.html)
AU (1) AU2005252226A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0511695A (cg-RX-API-DMAC7.html)
CA (1) CA2569395A1 (cg-RX-API-DMAC7.html)
IL (1) IL179631A0 (cg-RX-API-DMAC7.html)
MA (1) MA28902B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06013916A (cg-RX-API-DMAC7.html)
NO (1) NO20066016L (cg-RX-API-DMAC7.html)
RU (1) RU2006146042A (cg-RX-API-DMAC7.html)
WO (1) WO2005121065A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200610835B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
MXPA06013916A (es) * 2004-06-03 2007-03-07 Theravance Inc Agosnistas del receptor adrenergico beta2 de diamina.
EP1778638A1 (en) * 2004-07-21 2007-05-02 Theravance, Inc. Diaryl ether beta2 adrenergic receptor agonists
WO2006031556A2 (en) * 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008041914A1 (en) * 2006-10-06 2008-04-10 Astrazeneca Ab 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EA201001129A1 (ru) 2008-01-11 2011-02-28 Новартис Аг Пиримидины в качестве ингибиторов киназы
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY31905A (es) 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2379507B1 (en) 2008-12-30 2013-10-16 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
ES2551592T3 (es) 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1158082B (de) 1960-12-17 1963-11-28 Gruenenthal Chemie Verfahren zur Herstellung von Alkylendiaminderivaten und deren Salzen
BE630296A (cg-RX-API-DMAC7.html) 1962-03-31
US3775477A (en) * 1971-03-10 1973-11-27 Sterling Drug Inc N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
BE794414A (fr) * 1972-01-25 1973-07-23 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicament
GB1460593A (en) * 1973-06-22 1977-01-06 Ici Ltd Ethanolamine derivatives
JPS5913510B2 (ja) 1975-12-26 1984-03-30 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS5283619A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Alpha-substituted aminomethyl benzyl alcohol derivative
JPS609713B2 (ja) 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
GB8426200D0 (en) * 1984-10-17 1984-11-21 Glaxo Holdings Ltd Chemical compounds
GB8507942D0 (en) 1985-03-27 1985-05-01 Beecham Group Plc Compounds
AU6747387A (en) 1986-01-11 1987-07-16 Beecham Group Plc Arylethanolamine derivatives
US5223614A (en) * 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9713819D0 (en) * 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AU5629301A (en) * 2000-04-27 2001-11-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) * 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
MXPA04002405A (es) 2001-09-14 2004-05-31 Glaxo Group Limetd Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
AU2003239880A1 (en) * 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
MXPA06013916A (es) * 2004-06-03 2007-03-07 Theravance Inc Agosnistas del receptor adrenergico beta2 de diamina.

Similar Documents

Publication Publication Date Title
JP2008501705A5 (cg-RX-API-DMAC7.html)
RU2006146042A (ru) Диаминные агонисты 2-адренергических рецепторов
JP2007518738A5 (cg-RX-API-DMAC7.html)
CN103501776A (zh) 甘罗铵与β2激动剂的组合物
JP2006182786A5 (cg-RX-API-DMAC7.html)
JP2020500862A5 (cg-RX-API-DMAC7.html)
JP2005533860A5 (cg-RX-API-DMAC7.html)
JP2018199684A5 (cg-RX-API-DMAC7.html)
JP2006503850A5 (cg-RX-API-DMAC7.html)
CA2563302A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
JP2009543860A5 (cg-RX-API-DMAC7.html)
JP2005527618A5 (cg-RX-API-DMAC7.html)
RU2010108640A (ru) Новая комбинация терапевтических агентов
JP2004507465A5 (cg-RX-API-DMAC7.html)
RU2010126063A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора
JP2013531056A5 (cg-RX-API-DMAC7.html)
JP2006507220A5 (cg-RX-API-DMAC7.html)
JP2007505931A5 (cg-RX-API-DMAC7.html)
JP2003519228A5 (cg-RX-API-DMAC7.html)
RU2008124833A (ru) Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций
JP2009513713A5 (cg-RX-API-DMAC7.html)
JP2022520990A (ja) 呼吸器疾患の治療の方法
JP2005535578A (ja) トルテロジン塩
AU2003240113B2 (en) Formulation of nefopam and its use in the treatment of pain
CA2859004A1 (en) Methods and compositions for administration of oxybutynin